BranchLab, an AI platform designed to streamline biopharma commercialization, has closed a $26.0M Series A funding round. The capital infusion saw participation from McKesson Ventures, FCA Venture Partners, Sanofi Ventures, and AIX Ventures.
The company's platform allows biopharma companies and their marketing agencies to model high-value patient and provider populations, activate omnichannel strategies, and measure real-world outcomes without relying on personal health data. This approach aims to modernize how new therapies reach the market in the AI era.











.png&w=3840&q=75)



